The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Williams Textbook of Endocrinology
(2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,711
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Self-citationThe many faces of macrophage activation
Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Pathology and genetics of tumours of endocrine organs
DeLellis, R. A. (2004) · Cited by 1,122
Kavalieratos, D., Corbelli, J., Zhang, D., Dionne-Odom, J. N., Ernecoff, N. C., Hanmer, J., Hoydich, Z. P., Ikejiani, D. Z., Klein-Fedyshin, M., Zimmermann, C., et al. (2016) · JAMA · doi:10.1001/jama.2016.16840 · Cited by 1,121
The origin and function of tumor-associated macrophages
Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., & Ruco, L. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90008-u · Cited by 1,089
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
Self-citationDysregulation of the TSC-mTOR pathway in human disease
Inoki, K., Corradetti, M. N., & Guan, K.-L. (2005) · Nature Genetics · doi:10.1038/ng1494 · Cited by 972
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02654-4 · Cited by 847
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Gilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
Chang, C.-J., Chao, C.-H., Xia, W., Yang, J.-Y., Xiong, Y., Li, C.-W., Yu, W.-H., Rehman, S. K., Hsu, J. L., Lee, H.-H., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2173 · Cited by 745
International patterns and trends in thyroid cancer incidence, 1973–2002
Kilfoy, B. A., Zheng, T., Holford, T. R., Han, X., Ward, M. H., Sjodin, A., Zhang, Y., Bai, Y., Zhu, C., Guo, G. L., et al. (2009) · Cancer Causes & Control · doi:10.1007/s10552-008-9260-4 · Cited by 712
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors
Kebebew, E., Greenspan, F. S., Clark, O. H., Woeber, K. A., & McMillan, A. (2005) · Cancer · doi:10.1002/cncr.20936 · Cited by 666
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B.-C., & Wilson, K. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403319200 · Cited by 635
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Volante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180309e6a · Cited by 619
Williams Textbook of Endocrinology
Stoffer, S. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490110109043 · Cited by 608
MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility
Nikiforova, M. N., Tseng, G. C., Steward, D., Diorio, D., & Nikiforov, Y. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2696 · Cited by 582
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases
Venkatesh, Y. S. S., Ordonez, N. G., Schultz, P. N., Hickey, R. C., Goepfert, H., & Samaan, N. A. (1990) · Cancer · doi:10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a · Cited by 486
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
Smallridge, R. C., & Copland, J. A. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.013 · Cited by 481
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
Anaplastic Thyroid Carcinoma: A Study of 70 Cases
Carcangiu, M. L., Steeper, T., Zampi, G., & Rosai, J. (1985) · American Journal of Clinical Pathology · doi:10.1093/ajcp/83.2.135 · Cited by 469
Shimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
Ryder, M., Ghossein, R. A., Ricarte-Filho, J. C. M., Knauf, J. A., & Fagin, J. A. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0036 · Cited by 443
Sakamoto, A., Kasai, N., & Sugano, H. (1983) · Cancer · doi:10.1002/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x · Cited by 438
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas
Visone, R., Pallante, P., Vecchione, A., Cirombella, R., Ferracin, M., Ferraro, A., Volinia, S., Coluzzi, S., Leone, V, Borbone, E., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210564 · Cited by 391
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Baffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu-Lowe, D., & McDonald, D. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00616.2005 · Cited by 374
Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., & Pierotti, M. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116385 · Cited by 370
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
Kunstman, J. W., Juhlin, C. C., Goh, G., Brown, T. C., Stenman, A., Healy, J. M., Rubinstein, J. C., Choi, M., Kiss, N., Nelson-Williams, C., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu749 · Cited by 364
Aldinger, K. A., Samaan, N. A., Ibanez, M., & Hill, C. S. (1978) · Cancer · doi:10.1002/1097-0142(197806)41:6<2267::aid-cncr2820410627>3.0.co;2-7 · Cited by 364
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 352
Self-citationComputational modeling of the EGF-receptor system: a paradigm for systems biology
Steven Wiley, H. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)00009-0 · Cited by 345
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Wagle, N., Grabiner, B. C., Van Allen, E. M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J. A., Guo, Y., Swanson, S. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321
Molecular Diagnostics and Predictors in Thyroid Cancer
Nikiforova, M. N., & Nikiforov, Y. E. (2009) · Thyroid · doi:10.1089/thy.2009.0240 · Cited by 309
Ain, K. B., Egorin, M. J., DeSimone, P. A., & Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group* (2000) · Thyroid · doi:10.1089/thy.2000.10.587 · Cited by 295
Haigh, P. I., Ituarte, P. H. G., Wu, H. S., Treseler, P. A., Posner, M. D., Quivey, J. M., Duh, Q. Y., & Clark, O. H. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2335::aid-cncr1266>3.0.co;2-1 · Cited by 292
Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas
Braun, J., Hoang-Vu, C., Dralle, H., & Hüttelmaier, S. (2010) · Oncogene · doi:10.1038/onc.2010.169 · Cited by 282
Elisei, R., Romei, C., Vorontsova, T., Cosci, B., Veremeychik, V., Kuchinskaya, E., Basolo, F., Demidchik, E. P., Miccoli, P., Pinchera, A., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7678 · Cited by 275
Self-citationKelly, L. M., Barila, G., Liu, P., Evdokimova, V. N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S. E., Hodak, S. P., Luo, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321937111 · Cited by 271
Anaplastic Thyroid Carcinoma: Behavior, Biology, and Therapeutic Approaches
AIN, K. B. (1998) · Thyroid · doi:10.1089/thy.1998.8.715 · Cited by 265
Regulation and targets of receptor tyrosine kinases
Pawson, T. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80597-4 · Cited by 264
Oncogenic role of miR‐17‐92 cluster in anaplastic thyroid cancer cells
Takakura, S., Mitsutake, N., Nakashima, M., Namba, H., Saenko, V. A., Rogounovitch, T. I., Nakazawa, Y., Hayashi, T., Ohtsuru, A., & Yamashita, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00800.x · Cited by 242
Anaplastic carcinoma of the thyroid: A 24‐year experience
Tan, R. K. L., Finley, R. K., Driscoll, D., Bakamjian, V. Y., Hicks, W. L., & Shedd, D. P. (1995) · Head & Neck · doi:10.1002/hed.2880170109 · Cited by 237
Tennvall, J., Lundell, G., Wahlberg, P., Bergenfelz, A., Grimelius, L., Åkerman, M., Hjelm Skog, A.-L., & Wallin, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600361 · Cited by 235
Nikiforov, Y. E. (2004) · Endocrine Pathology · doi:10.1385/ep:15:4:319 · Cited by 234
Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Savvides, P., Nagaiah, G., Lavertu, P., Fu, P., Wright, J. J., Chapman, R., Wasman, J., Dowlati, A., & Remick, S. C. (2013) · Thyroid · doi:10.1089/thy.2012.0103 · Cited by 219
The pediatric cancer quality of life inventory-32 (PCQL-32): I. Reliability and validity
Varni, J. W., Katz, E. R., Seid, M., Quiggins, D. J. L., & Friedman-Bender, A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980315)82:6<1146::aid-cncr20>3.0.co;2-5 · Cited by 217
Lenvatinib: Role in thyroid cancer and other solid tumors
Cabanillas, M. E., & Habra, M. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.003 · Cited by 208
Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates
Jung, K. Y., Cho, S. W., Kim, Y. A., Kim, D., Oh, B.-C., Park, D. J., & Park, Y. J. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.06.01 · Cited by 206
Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding.
Böni-Schnetzler, M., & Pilch, P. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7832 · Cited by 205
Lenvatinib for Anaplastic Thyroid Cancer
Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., Toda, K., Enokida, T., Minami, H., Imamura, Y., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00025 · Cited by 198
A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
Pennell, N. A., Daniels, G. H., Haddad, R. I., Ross, D. S., Evans, T., Wirth, L. J., Fidias, P. H., Temel, J. S., Gurubhagavatula, S., Heist, R. S., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0120 · Cited by 197
The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma
Pierie, J. P. E. N., Muzikansky, A., Gaz, R. D., Faquin, W. C., & Ott, M. J. (2002) · Annals of Surgical Oncology · doi:10.1245/aso.2002.9.1.57 · Cited by 195
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Murugan, A. K., & Xing, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4041 · Cited by 193
Caillou, B., Talbot, M., Weyemi, U., Pioche-Durieu, C., Al Ghuzlan, A., Bidart, J. M., Chouaib, S., Schlumberger, M., & Dupuy, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022567 · Cited by 191
Casali, P. G., Jost, L., Reichardt, P., Schlemmer, M., & Blay, J.-Y. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn080 · Cited by 187
Bastman, J. J., Serracino, H. S., Zhu, Y., Koenig, M. R., Mateescu, V., Sams, S. B., Davies, K. D., Raeburn, C. D., McIntyre, R. C., Haugen, B. R., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4227 · Cited by 181
Mooney, C. J., Nagaiah, G., Fu, P., Wasman, J. K., Cooney, M. M., Savvides, P. S., Bokar, J. A., Dowlati, A., Wang, D., Agarwala, S. S., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0321 · Cited by 180
BRAF V600E Inhibition in Anaplastic Thyroid Cancer
Rosove, M. H., Peddi, P. F., & Glaspy, J. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215697 · Cited by 179
Genome-Wide Appraisal of Thyroid Cancer Progression
Wreesmann, V. B., Ghossein, R. A., Patel, S. G., Harris, C. P., Schnaser, E. A., Shaha, A. R., Tuttle, R. M., Shah, J. P., Rao, P. H., & Singh, B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64433-1 · Cited by 178
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Bible, K. C., Suman, V. J., Menefee, M. E., Smallridge, R. C., Molina, J. R., Maples, W. J., Karlin, N. J., Traynor, A. M., Kumar, P., Goh, B. C., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1520 · Cited by 175
Diagnostic pathology and molecular genetics of the thyroid
Nikiforov, Y. E., Biddinger, P. W., & Thompson, L. D. �. (2009) · Cited by 174
Fujita, K., Ikarashi, H., Takakuwa, K., Kodama, S., Tokunaga, A., Takahashi, T., & Tanaka, K. (1995) · PubMed · Cited by 171
Sosa, J. A., Elisei, R., Jarząb, B., Balkissoon, J., Lu, S.-P., Bal, C., Marur, S., Gramza, A. W., Ben‐Yosef, R., Gitlitz, B. J., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0078 · Cited by 151
Self-citationLim, S., Chang, H. K., Yoon, M. J., Hong, Y. K., Kim, H., Chung, W. Y., Park, C. S., Nam, K., Kang, S., Kim, M. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt379 · Cited by 147
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system
Polier, S., Samant, R. S., Clarke, P. A., Workman, P., Prodromou, C., & Pearl, L. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1212 · Cited by 145
p53 Gene Mutations Associated with Anaplastic Transformation of Human Thyroid Carcinomas
Nakamura, T., Yana, I., Kobayashi, T., Shin, E., Karakawa, K., Fujita, S., Miya, A., Mori, T., Nishisho, I., & Takai, S. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb02761.x · Cited by 138
Kim, S., Yazici, Y. D., Calzada, G., Wang, Z.-Y., Younes, M. N., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0595 · Cited by 138
Chintakuntlawar, A. V., Rumilla, K. M., Smith, C. Y., Jenkins, S. M., Foote, R. L., Kasperbauer, J. L., Morris, J. C., Ryder, M. M., Alsidawi, S., Hilger, C. R., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3756 · Cited by 137
Murugan, A. K., Bojdani, E., & Xing, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.095 · Cited by 135
Copland, J. A., Marlow, L. A., Kurakata, S., Fujiwara, K., Wong, A., Kreinest, P. A., Williams, S. F., Haugen, B. R., Klopper, J. P., & Smallridge, R. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209267 · Cited by 134
A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer
Ha, H. T., Lee, J. J., Urba, S. G., Koenig, R. J., Sisson, J. C., Giordano, T. J., & Worden, F. P. (2010) · Thyroid · doi:10.1089/thy.2010.0057 · Cited by 129
Mitsiades, C. S., McMillin, D. W., Kotoula, V., Poulaki, V., McMullan, C. J., Negri, J. M., Fanourakis, G., Tseleni‐Balafouta, S., Ain, K. B., & Mitsiades, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2472 · Cited by 128
Miettinen, M., & Franssila, K. (2000) · Human Pathology · doi:10.1053/hupa.2000.16667 · Cited by 124
Smallridge, R. C., Copland, J. A., Brose, M. S., Wadsworth, J. T., Houvras, Y. J., Menefee, M. E., Bible, K. C., Shah, M. H., Gramza, A. W., Klopper, J. P., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1106 · Cited by 114
Kono, K., Takahashi, A., Ichihara, F., Amemiya, H., Iizuka, H., Fujii, H., Sekikawa, T., & Matsumoto, Y. (2002) · PubMed · Cited by 112
Sorafenib in metastatic thyroid cancer
Capdevila, J., Iglesias, L., Halperín, I., Segura, Á., Martínez‐Trufero, J., Salgado, M. Á. V., Corral, J., Obiols, G., Grande, E., Grau, J. J., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0351 · Cited by 112
Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis
Charles, R., Silva, J. M., Iezza, G., Phillips, W. A., & McMahon, M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0158-t · Cited by 109
Pita, J. M. G., Figueiredo, I., Moura, M. M., Leite, V. A. P. H., & Cavaco, B. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1512 · Cited by 103
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint
Marotta, V., Guerra, A., Sapio, M. R., & Vitale, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0499 · Cited by 101
Leroy, B., Ballinger, M. L., Baran‐Marszak, F., Bond, G. L., Braithwaite, A. W., Concin, N., Donehower, L. A., El‐Deiry, W. S., Fenaux, P., Gaïdano, G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2179 · Cited by 97
Kim, S., Prichard, C. N., Younes, M. N., Yazici, Y. D., Jasser, S. A., Bekele, B. N., & Myers, J. N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1325 · Cited by 95
Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
Pérot, G., Soubeyran, I., Ribeiro, A., Bonhomme, B., Savagner, F., Boutet-Bouzamondo, N., Hostein, I., Bonichon, F., Godbert, Y., & Chibon, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087170 · Cited by 94
E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
Glen, H., Mason, S. M., Patel, H., MacLeod, K. G., & Brunton, V. G. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-309 · Cited by 86
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas
Hemerly, J. P., Bastos, A. U., & Cerutti, J. M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0473 · Cited by 84
The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells
Podtcheko, A., Ohtsuru, A., Tsuda, S., Namba, H., Saenko, V., Nakashima, M., Mitsutake, N., Kanda, S., Kurebayashi, J., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021230 · Cited by 82
MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology
Fuziwara, C. S., & Kimura, E. T. (2014) · International Journal of Endocrinology · doi:10.1155/2014/743450 · Cited by 81
Jeon, M. J., Chun, S., Kim, D., Kwon, H., Jang, E. K., Kim, T. Y., Kim, W. B., Shong, Y. K., Jang, S. J., Song, D. E., et al. (2016) · Thyroid · doi:10.1089/thy.2015.0506 · Cited by 79
Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer
Isham, C. R., Bossou, A. R., Negron, V. C., Fisher, K. E., Kumar, R., Marlow, L. A., Lingle, W. L., Smallridge, R. C., Sherman, E. J., Suman, V. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004358 · Cited by 69
Changing patterns of thyroid carcinoma
Dijkstra, B., Prichard, R. S., Lee, A., Kelly, L. M., Smyth, P. P. A., Crotty, T. B., McDermott, E. W. M., Hill, A. D. K., & O’Higgins, N. J. (2007) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-007-0041-y · Cited by 64
Gastrointestinal Stromal Tumor: A Clinical Overview
Quek, R. H. H., & George, S. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.11.006 · Cited by 58
Bikas, A., Kundra, P., Desale, S. Y., Mete, M., O'Keefe, K., Clark, B. G., Wray, L., Gandhi, R., Barett, C., Jelinek, J. S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0930 · Cited by 58
Oguchi, H., & Kimura, S. (1998) · Endocrinology · doi:10.1210/endo.139.4.5933 · Cited by 57
Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma
Nachalon, Y., Shavit, S. S., Bachar, G. Y., Shvero, J., Limon, D., & Popovtzer, A. (2015) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2015.2332 · Cited by 55
Suzuki, K., MORI, A., Lavaroni, S., Miyagi, E., Ulianich, L., Katoh, R., Kawaoi, A., & Kohn, L. D. (1999) · Thyroid · doi:10.1089/thy.1999.9.319 · Cited by 52
Epidermal Growth Factor Receptor as a Novel Therapeutic Target in Anaplastic Thyroid Carcinomas
Ensinger, C., Spizzo, G., Moser, P. L., Tschörner, I., Prommegger, R., Gabriel, M., Mikuz, G., & Schmid, K. W. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1329.009 · Cited by 44
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma
Voigt, W., Kegel, T., Weiss, M., Mueller, T., Simon, H., & Schmoll, H. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0673-0 · Cited by 41
Gomez‐Rivera, F., Santillan-Gomez, A. A., Younes, M. N., Kim, S. W., Fooshee, D. R., Zhao, M., Jasser, S. A., & Myers, J. N. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2636 · Cited by 40
Desidero, T. D., Fioravanti, A., Orlandi, P., Canu, B., Giannini, R., Borrelli, N., Man, S., Xu, P., Fontanini, G., Basolo, F., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1364 · Cited by 39
Self-citationLai, M. B., Bhardwaj, V., Lai, J. C. K., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4403 · Cited by 38
Bellevicine, C., Vigliar, E., Malapelle, U., Carelli, E., Fiorelli, A., Vicidomini, G., Cappabianca, S., Santini, M., & Troncone, G. (2015) · Diagnostic Cytopathology · doi:10.1002/dc.23264 · Cited by 25
Pazopanib alone is not effective against anaplastic thyroid cancer
McLarnon, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.136 · Cited by 12
Hishinuma, A., Takamatsu, J., Kanno, Y., YOSHIDA, S., & Ieiri, T. (1998) · Thyroid · doi:10.1089/thy.1998.8.305 · Cited by 9
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Patel, K. N., Yip, L., Lubitz, C. C., Grubbs, E. G., Miller, B. S., Shen, W., Angelos, P., Chen, H., Doherty, G. M., Fahey, T. J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003580 · Cited by 541
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
Yoo, S.-K., Song, Y. S., Lee, E. K., Hwang, J., Kim, H. H., Jung, G., Kim, Y. A., Kim, S.-J., Cho, S. W., Won, J.-K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10680-5 · Cited by 268
Zhang, L., Lian, R., Zhao, J., Feng, X., Ye, R., Pan, L., Wu, J., Li, M., Huang, Y., & Cai, J. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0310-2 · Cited by 36
Metadata
- Authors
- Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., Basolo, F., Vitti, P., & Elisei, R.
- Venue
- Nature Reviews Endocrinology
- Published
- 2017-07-14
- Volume
- 13
- Issue
- 11
- Pages
- 644-660
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W2736254713
- Cited by
- 483
- References
- 132
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.